Introduction

Leptin is one of the most important hormones secreted by the adipocytes [1]. Besides regulating food intake and energy expenditure [2], leptin plays an essential role in hematopoiesis, reproductive function, and glucose and lipid metabolism [3]. More recently, leptin has also been linked to cancer [4]. Enhanced expressions of leptin and its receptor (Ob-R) are found in solid cancers including breast and ovarian cancers, and have been associated to metastasis and poor prognosis [5, 6]. However, conflicting evidence exists in the context of cancer incidence. For instance, in a meta analysis comprising 23 case–control studies, a protective effect of serum leptin against postmenopausal breast cancer was reported [7]. In contrast, a positive association was seen in recent nested case–control studies, where serum leptin was measured prospectively prior to diagnosis in breast cancer cases [8, 9]. Meanwhile, circulating Ob-R has been linked to a lower risk of colorectal cancer in a nested case–control study despite a null finding for leptin [10]. These inconsistent findings may reflect an involvement of other factors in the relationship between leptin and carcinogenesis, as well as potential time-sensitivity of this association.

Serum leptin, C-reactive protein, and cancer mortality in the NHANES III

Wahyu Wulaningsih¹, Lars Holmberg²,³, Tony Ng⁴, Sabine Rohrmann⁵ & Mieke Van Hemelrijck¹

¹Cancer Epidemiology Group, Division of Cancer Studies, School of Medicine, King’s College London, London, United Kingdom
²Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
³Regional Cancer Centre, Uppsala University, Uppsala, Sweden
⁴Randall Division and Division of Cancer Studies, Richard Dimbleby Department of Cancer Research, School of Medicine, King’s College London, London, United Kingdom
⁵Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland

Keywords
Cancer, C-reactive protein, leptin, mortality, prospective study

Abstract

Adipokines, such as leptin, may affect cancer through its link with inflammation and obesity. We investigated the association between leptin, C-reactive protein, and risk of cancer death while accounting general and abdominal obesity. From the Third National Health and Examination Survey (NHANES III), we selected 5957 adult men and women with baseline measurements of serum leptin and CRP. Multivariable Cox regression was used to assess leptin and CRP levels (low, moderate, high) in relation to risk of cancer death. Stratification analyses were performed for obesity as defined by body mass index (BMI) and waist circumference. Fine and Gray regression was performed to account for death from cardiovascular disease and other causes as competing events. A total of 385 participants died of cancer during a mean follow-up of 18 years. After adjusting for BMI and waist circumference, an inverse association with log-transformed leptin was found for women, with a hazard ratio (HR) of 0.81 (95% confidence interval [CI]: 0.51–1.30) and 0.40 (95% CI: 0.24–0.68) for moderate and high compared to low levels of leptin, respectively; \( P_{\text{trend}} = 0.0007 \). No association for leptin was observed in men, but higher CRP corresponded to increased risk of dying from cancer (HR: 2.98; 95% CI: 1.57–5.64 for the highest vs. lowest categories of CRP). Similar associations were observed with competing risk analysis also adjusted for BMI and waist circumference. Contrasting associations of serum leptin and CRP with cancer mortality may indicate sex-specific biological or environmental pathways linking obesity and cancer in men and women which warrant mechanistic investigations.
Obesity may promote the development of cancer [11], but their mechanistic association remains unclear. There is indication that chronic inflammation may mediate obesity and cancer [12]. Interestingly, a role of leptin in inflammation has been suggested [13], as shown by a linear association between leptin and markers of inflammation [14]. Both increased inflammatory activity and leptin production are common features of obesity [15], thus it remains unclear whether pathways linking obesity and the development of cancer involve leptin production or inflammation, or whether there are simultaneous effects of these two processes on cancer susceptibility.

Presently, there is lack of observational studies assessing leptin in relation to cancer while accounting for inflammation and different definitions of obesity. Therefore, we sought to disentangle this complex association between leptin, inflammation and cancer by assessing serum levels of leptin and C-reactive protein (CRP), a common inflammatory marker [16], in relation to cancer mortality in the Third National Health and Nutrition Examination Survey (NHANES III) while accounting for general and abdominal obesity. Additionally, since both markers are linked to death from cardiovascular disease [17], we used cardiovascular mortality as a competing outcome in our analysis.

Methods

Study population

The National Center for Health Statistics (NCHS) conducted NHANES III between 1988 and 1994 and designed it as a multistage stratified, clustered probability sample of the U.S. civilian noninstitutionalized population who was at least 2 months old. All subjects participated in an interview conducted at home and an extensive physical examination, which included a blood sample taken in a mobile examination center [18]. Despite a cross-sectional design, mortality follow-up was provided by the NCHS through December 31, 2011, allowing the use of the dataset as a prospective cohort [19]. From recruited NHANES III participants, we selected 5957 men and women aged 20 and over who had baseline measurements of serum leptin and CRP, available information on body mass index (BMI) and waist circumference, and for whom follow-up information was available. No participant reported a history of any cancer at the baseline interview. The protocols for the conduct of NHANES III were approved by the Institutional Review Board of the NCHS, Centers for Disease Control and Prevention. Written informed consent was obtained from all participants [18].

Serum leptin and CRP measurements

Serum specimens were stored at −70°C and went through at least one freeze–thaw cycle during a mean of 8 year of storage before leptin concentrations were measured. Serum leptin was measured by radioimmunoassay at Linco Research, Inc. (St Charles, MO) [20]. The minimum detectable concentration of the assay is 0.5 ng/mL. Within- and between-assays coefficients of variation were <5%. Levels of serum leptin were categorized into low, moderate, and high based on sex-specific tertiles [21], with cut-off points of 3.3 and 6.3 μg/L for men and 10.8 and 20 μg/L for women. Serum CRP was measured with an automated Behring Nephelometer Analyzer System (Behring Diagnostics, Inc, Somerville, NJ) [22]. Coefficients of variation ranged from 3.2 to 16.0% throughout data collection. Tests were repeated for specimens with results of >10 mg/L. Because levels of CRP below 2.2 mg/L were undetectable in the NHANES III, we used clinical cut-off points as previously described [16]: low (<2.2 mg/L), moderate (2.2–10 mg/L), and high (≥10 mg/L).

Covariates

Information on age (years), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican American, and other), cigarette smoking (never, former, and current smokers), alcohol consumption (never, up to once/week, 2–3 times/week, 4–6 times/week, daily or more), vigorous physical activity (yes, no), and self-reported history of cancer (yes, no) was collected during the interview. Socioeconomic status was estimated with poverty-to-income ratio (PIR), a ratio of total family income to the official poverty threshold at the family level. A PIR <1 indicated that income was less than the level of poverty. We categorized PIR in this study into <1, 1–2, and ≥2.

Obesity status

Body measurements were performed using standardized methods and equipment [23]. Weight was measured in pounds and automatically converted to kilograms with an electronic weight scale. Participants only wore under-wear, disposable paper gowns, and foam rubber slippers. Standing height was measured with a fixed stadiometer to the nearest 1 mm. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters. Waist circumference was measured at the high point of the iliac crest at minimal respiration using a steel measuring tape to the nearest 1 mm [23]. General obesity (obese, not obese) was defined as having a BMI of 30 kg/m² or more [24]. Abdominal obesity (obese, not obese) was defined as waist circumference of >102 cm in men and >88 cm in women [25].

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Mortality and follow-up

Information on dates and causes of death was obtained from data linkage of the NHANES dataset with the National Death Index (NDI). This linkage was performed by the NCHS through probabilistic matching with social security number, birth date, occupation, and other personal data, and confirmation with death certificate when possible [19]. Follow-up time was calculated from interview date/examination date until date of death or end of study (31 December, 2011), whichever came first. Underlying causes of death were based on ICD-9 codes through 1998 and on International Classification of Diseases, 10th version (ICD-10) codes for deaths occurring after 1998. In order to adjust for changes between the two coding systems, final cause of deaths occurring prior to 1999 were re-coded into comparable ICD-10-based underlying cause of death groups [19]. The primary outcome of this study was cancer-specific death (ICD-10: C00-C97). Only aggregate information on leading causes of death is available in the 2011 mortality follow-up, thus rendering analysis by specific cancer sites not possible. Death from major cardiovascular diseases (ICD-10: I00-I09, I11, I13, I20-I51, I60-I69) and other causes were assessed as competing outcomes.

Statistical analysis

Sampling weights for NHANES III were used to account for sampling variability and to adjust for differential probability of selection of persons [18]. Due to differential distribution of serum leptin in men and women, we performed our analysis for men and women separately. Cox proportional hazards regression was used to assess risk of cancer death by categories of CRP and leptin. A test for trend was conducted by using assignment to categories as an ordinal scale. First, we carried out our analyses using two multivariable models: the first was adjusted for age, race/ethnicity, PIR, tobacco smoking, alcohol consumption, and vigorous physical activity. The final model included BMI and waist circumference to account for the effects of obesity. A test for multiplicative interaction between leptin and CRP was performed based on the suggested correlation between the two variables [21]. To further elucidate potential effect modification by obesity [16], we stratified our analysis based on general obesity status while adjusting for waist circumference, and by abdominal obesity while adjusting for BMI. In addition to interaction between leptin and CRP, we also assessed the interaction of each marker with obesity status. Finally, since the association of both markers and cardiovascular death [17] may affect their impact on cancer mortality, we performed Fine and Gray regression with deaths from major cardiovascular diseases and other causes as competing outcomes. The Fine and Gray analysis has been used to predict cumulative incidence of primary outcome in presence of competing outcomes, which may have created a competing risks situation [26]. We treated categories of leptin and CRP as ordinal variables and adjusted the models for age, race/ethnicity, PIR, tobacco smoking, alcohol consumption, vigorous physical activity, BMI, and waist circumference. Statistical significance was defined as two-sided \( P \)-values <0.05. All analyses were conducted with SAS release 9.3 (SAS Institute, Cary, NC) and R version 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).

Results

During a mean follow-up of 18 years, a total of 385 participants died of cancer and 507 from major cardiovascular diseases. Table 1 showed weighted characteristics of study participants by sex. Overall, increased leptin levels and by abdominal obesity while adjusting for BMI. In addition to interaction between leptin and CRP, we also assessed the interaction of each marker with obesity status. Finally, since the association of both markers and cardiovascular death [17] may affect their impact on cancer mortality, we performed Fine and Gray regression with deaths from major cardiovascular diseases and other causes as competing outcomes. The Fine and Gray analysis has been used to predict cumulative incidence of primary outcome in presence of competing outcomes, which may have created a competing risks situation [26]. We treated categories of leptin and CRP as ordinal variables and adjusted the models for age, race/ethnicity, PIR, tobacco smoking, alcohol consumption, vigorous physical activity, BMI, and waist circumference. Statistical significance was defined as two-sided \( P \)-values <0.05. All analyses were conducted with SAS release 9.3 (SAS Institute, Cary, NC) and R version 3.1.0 (R Foundation for Statistical Computing, Vienna, Austria).

Table 1. Weighted characteristics of study population by sex.

|                      | Men (N = 2759) | Women (N = 3198) |
|----------------------|---------------|------------------|
| Age (years) – Mean (SD) | 42.64 (0.55) | 43.81 (0.60) |
| Follow-up (years)     | 19.35 (17.53–20.95) | 19.38 (17.65–20.94) |
| – Median (IQR\(^3\))  |               |                  |
| Race – Ethnicity (%)  |               |                  |
| Non-Hispanic white    | 76.52         | 76.42            |
| Non-Hispanic black    | 9.77          | 11.32            |
| Mexican American      | 5.56          | 4.78             |
| Other                 | 8.16          | 7.48             |
| Poverty-to-income ratio |             |                  |
| <1                   | 16.34         | 19.89            |
| 1–2                  | 19.09         | 19.97            |
| ≥2                   | 64.57         | 60.14            |
| Alcohol consumption (%) |              |                  |
| Never                | 35.09         | 51.69            |
| Up to once/week      | 18.15         | 21.28            |
| 2–3 times/week       | 16.50         | 13.11            |
| 4–6 times/week       | 15.44         | 8.19             |
| Daily or more        | 14.82         | 5.73             |
| Smoking behavior (%)  |               |                  |
| Never                | 36.36         | 55.53            |
| Former               | 32.29         | 20.13            |
| Current              | 31.35         | 24.34            |
| Vigorous Physical activity (%) |          |                  |
| Waist circumference (cm) – Mean (SD) | 95.50 (0.48) | 88.22 (0.47) |
| Body mass index (kg/m\(^2\)) |              |                  |
| <18.5                | 0.68          | 2.981            |
| 18.5–25              | 38.57         | 46.04            |
| 25–30                | 40.46         | 27.06            |
| ≥30                  | 20.28         | 24.09            |
| Cancer death (%)     | 4.72          | 5.15             |
| Cardiovascular death (%) | 6.34        | 4.80             |

\(^3\)Interquartile range.
with the highest concentrations of leptin seen in men and women with high CRP and BMI ≥ 30 kg/m² or the upper category of waist circumference.

When we examined the association between serum leptin or CRP and cancer death with the first model, high levels of CRP in men corresponded to higher risk of dying from cancer, with a hazard ratio (HR) of 2.98 and 95% confidence interval (CI) of 1.57 to 5.64 for the highest category of CRP compared to the lowest. No association was observed between leptin and cancer death in both sexes (Table 2). We further adjusted this model for obesity indicators, BMI and waist circumference, and no changes were seen with CRP. However, this revealed a marked inverse association between serum leptin and risk of cancer death in both sexes (Table 2). We sought to further unpick the effect of obesity by stratification analyses based on general and abdominal obesity status. In men, no association between serum leptin and cancer death was observed (Table 3). For CRP, higher levels in men without general obesity was observed (HR: 3.62; 95% CI: 1.86–7.04 for high compared to low CRP, $P_{\text{trend}} = 0.004$). Interestingly, a higher risk of cancer death with the highest CRP levels was also seen in men with abdominal obesity (HR: 3.43; 95% CI: 1.03–11.48 compared to low CRP) but not those without. Nevertheless, no significant interaction between each definition of obesity and CRP was found. On the other hand, higher serum leptin was inversely associated with cancer death in women with or without general obesity, for example, HR among women with BMI <30 kg/m² was 0.76 (95% 0.44–1.32) and 0.30 (0.14–0.65) for moderate and high compared to low leptin, respectively ($P_{\text{trend}} = 0.003$). Results were less clear in stratification by waist circumference, or when CRP was assessed (Table 3). No strong interaction between leptin and CRP was suggested, although among men with abdominal obesity, interaction approached statistical significance ($P = 0.07$). Nevertheless, in a follow-up analysis when we included leptin and CRP in the same model, similar findings were observed.

![Figure 1.](https://example.com/figure1.png)
Finally, to account for competing risks, we ran Fine and Gray regression to estimate cumulative mortality of cancer over time with levels of leptin or CRP as the predictor variable and deaths from major cardiovascular diseases and other causes as competing outcomes. The analysis was adjusted for all potential confounders including BMI and waist circumference. Men with higher CRP were shown to have higher cumulative mortality from cancer over time \( (P = 0.009) \), whereas no association for serum leptin was found \( (P_{\text{trend}} = 0.17) \). In women, serum CRP was not suggested to correlate with cancer mortality \( (P = 0.59) \). On the other hand, higher cumulative mortality from cancer was noted in women with higher serum leptin \( (P = 0.006) \). Therefore, our results from the competing risk analysis corroborated our findings from Cox regression models.

## Discussion

This study was based on a nationally representative sample of the U.S. population. We observed a protective effect of leptin against cancer death in women and higher cancer death with increased CRP in men. No marked interaction between leptin and CRP was found. Similar associations were observed when competing risk analyses with deaths from major cardiovascular diseases and other causes as competing outcomes were employed.

Proposed mechanisms linking leptin and carcinogenesis mostly suggest that higher leptin exposure increases predisposition to the disease [3]. The long isoform of leptin receptor (Ob-R) is similar to a type I cytokine receptor, with an ability to activate downstream JAK/STAT signaling pathway, a known transcription activator for genes involved in cell proliferation, survival, angiogenesis, and metastasis [27]. Furthermore, the activation of ObR may lead to phosphorylation of insulin receptor substrate (IRS-1), initiating activation of PI3K/Akt pathway, which is also important in carcinogenesis [28]. Besides directly eliciting cancer-related signaling, leptin also displays proinflammatory properties [29]. Inflammation may also promote cancer by activation of signaling molecules including STAT3 and NF-κB [30]. Despite suggestive experimental findings, there is limited observational evidence documenting the importance of leptin-inflammation interplay in cancer incidence or mortality.

### Table 2. Sex-specific associations of serum leptin and C-reactive protein (CRP) with cancer death in the NHANES III.

|                  | Men                                                                 | Women                                                                 |
|------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                  | \( N \) cancer death/\( N \) total | HR (95% CI) | \( N \) cancer death/\( N \) total | HR (95% CI) | \( N \) cancer death/\( N \) total | HR (95% CI) |
| **Leptin (μg/L)**|                                                                     |                                                                     |
| Low              | 49/909                                                               | 1.0 (Reference) | 54/1081                                                               | 1.0 (Reference) |
| Moderate         | 71/962                                                               | 0.87 (0.51–1.49) | 71/1096                                                               | 1.19 (0.74–1.91) |
| High             | 79/964                                                               | 0.86 (0.50–1.47) | 61/1128                                                               | 0.93 (0.57–1.51) |
| ***P*** \_trend  | 0.60                                                                |                                                                     | 0.80                                                                |                                                                     |
| **CRP (mg/L)**   |                                                                     |                                                                     |
| Low              | 195/2047                                                             | 1.0 (Reference) | 103/2027                                                              | 1.0 (Reference) |
| Moderate         | 56/596                                                               | 1.33 (0.82–2.18) | 58/914                                                                | 1.41 (0.84–2.38) |
| High             | 34/192                                                               | 2.98 (1.57–5.64) | 61/1128                                                               | 0.93 (0.57–1.51) |
| ***P*** \_trend  | 0.003                                                               | 0.003                                                             | 0.80                                                                | 0.0007                                                             |
| **P** \_interaction leptin and CRP | 0.13                                                               | 0.13                                                             |                                                                     |                                                                     |

1 Adjusted for age (continuous) and waist circumference, race/ethnicity, poverty-to-income ratio (PIR), tobacco smoking, alcohol consumption, and vigorous physical activity.

2 Adjusted for age (continuous) and waist circumference, race/ethnicity, PIR, tobacco smoking, alcohol consumption, vigorous physical activity, body mass index (continuous) and waist circumference (continuous), and waist circumference.
Findings from population-based studies for the link between leptin and cancer are scarce. Some evidence suggests a positive association between prediagnostic serum leptin and risk of cancer for colorectal [31], breast [8], prostate [32], and endometrial cancer [33], as well as renal cell carcinoma [4], but results are contradictory [34, 35]. In a large nested case–control study based on the European Prospective Investigation into Cancer and Nutrition (EPIC), no association was reported between serum leptin and risk of colorectal cancer regardless further adjustment for BMI (RR: 0.85 (95% CI: 0.56–1.29) for the highest quintile compared to the lowest; \( P_{\text{trend}} = 0.76 \)) [10]. We found a lack of association between leptin and cancer death, whereas CRP was positively associated to cancer death in men. The inverse association for leptin, which was not observed in previous studies such as the EPIC Study focusing on colorectal cancer [10] might be attributed to the use of cancer mortality as an outcome instead of cancer incidence. Therefore, it is possible that leptin, despite being weakly associated to cancer incidence, may reflect susceptibility for fatal malignancies.

With respect to obesity, leptin and inflammation have gained increasing interest with regards to their potential implications in cancer development [12]. Leptin resistance may occur in obesity [36], where higher levels of leptin follow. Interestingly, CRP has been identified as one of the major serum leptin-interacting proteins (SLIPs) which may worsen leptin resistance [37] and support a biological interaction between leptin and CRP in the context of diseases. In this study, a nearly statistically significant interaction between leptin and CRP was observed in men with abdominal obesity. Romero-Corral and colleagues [21] stated that such interaction occurs when assessing cardiovascular disease, resulting in a weaker association between CRP and cardiovascular disease after adjustment for leptin. Nevertheless, we did not observe any alteration

| Table 3. | Sex-specific associations of serum leptin and C-reactive protein (CRP) with cancer death in the NHANES III, stratified by obesity status. All models were adjusted for age, race/ethnicity, poverty-to-income ratio (PIR), tobacco smoking, alcohol consumption, and vigorous physical activity. |
|----------|--------------------------------------------------|
|          | General obesity | Abdominal obesity |
|          | Not obese | Obese | Not obese | Obese |
| Men      |          |        |          |        |
| N cancer death/N total | 145/2177 | 43/582 | 114/1965 | 74/794 |
| Leptin (μg/L) |        |        |          |        |
| Low | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Moderate | 0.85 (0.50–1.44) | 1.18 (0.22–6.40) | 0.91 (0.47–1.76) | 4.09 (0.88–19.10) |
| High | 0.61 (0.24–1.53) | 1.56 (0.35–6.94) | 0.64 (0.20–1.99) | 2.71 (0.64–11.45) |
| \( P_{\text{trend}} \) | 0.28 | 0.56 | 0.49 | 0.59 |
| \( P_{\text{interaction}} \) leptin and obesity | 0.52 | 0.43 | 0.39 | 0.09 |
| CRP (mg/L) |        |        |          |        |
| Low | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Moderate | 0.99 (0.52–1.89) | 1.48 (0.41–5.40) | 1.06 (0.57–1.97) | 1.33 (0.63–2.79) |
| High | 3.62 (1.86–7.04) | 0.59 (0.13–2.72) | 2.22 (0.97–5.05) | 3.43 (1.03–11.48) |
| \( P_{\text{trend}} \) | 0.004 | 0.89 | 0.17 | 0.07 |
| \( P_{\text{interaction}} \) CRP and obesity | 0.29 | 0.64 | 0.39 | 0.09 |
| \( P_{\text{interaction}} \) leptin and CRP | 0.09 | 0.11 | 0.63 | 0.41 |
| Women |          |        |          |        |
| N cancer death/N total | 112/2235 | 67/963 | 52/1438 | 127/1760 |
| Leptin (μg/L) |        |        |          |        |
| Low | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Moderate | 0.76 (0.44–1.32) | 1.77 (0.20–16.16) | 1.06 (0.49–2.30) | 1.24 (0.64–2.41) |
| High | 0.30 (0.14–0.65) | 0.65 (0.08–5.08) | N/A | 1.07 (0.55–2.07) |
| \( P_{\text{trend}} \) | 0.003 | 0.01 | 0.15 | 0.09 |
| \( P_{\text{interaction}} \) leptin and obesity | 0.63 | 0.41 | 0.63 | 0.46 |
| CRP (mg/L) |        |        |          |        |
| Low | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) | 1.0 (Reference) |
| Moderate | 1.32 (0.66–2.63) | 0.89 (0.33–2.36) | 1.00 (0.47–2.11) | 1.29 (0.70–2.36) |
| High | 0.65 (0.25–1.68) | 0.92 (0.43–1.94) | N/A | 1.14 (0.62–2.07) |
| \( P_{\text{trend}} \) | 0.78 | 0.89 | 0.40 | 0.63 |
| \( P_{\text{interaction}} \) CRP and obesity | 0.83 | 0.35 | 0.77 | 0.46 |
| \( P_{\text{interaction}} \) leptin and CRP | 0.37 | 0.92 | 0.37 | 0.92 |

1Adjusted for waist circumference (continuous).
2Adjusted for body mass index (continuous).
in our findings after leptin and CRP were both included in the same analysis, thus suggesting minimal interaction between serum leptin and CRP with respect to cancer mortality as an outcome.

In many studies including ours, serum concentrations of leptin are positively correlated with that of CRP regardless of obesity [38, 39]. However, we observed different effects between leptin and CRP levels on cancer mortality. This may signify differential roles between leptin and CRP in the scope of cancer, which require further biological investigations. From the competing risk analysis where we took into account competing outcomes, it was further suggested the inverse association between serum leptin and cumulative mortality from cancer in women, and a positive association for CRP in men. Our findings therefore indicate that the associations between leptin or CRP and cancer may be unique and do not resemble the additive effects observed with cardiovascular disease [21]. This interesting observation may suggest different biological pathways linking leptin and inflammation with cancer, which may involve sex-specific biological and environmental factors. Such observations thus call for further investigations to assess specific cancers and relevant mechanistic approaches.

This strength of this study is its generalizability following the use of nationally representative data of the U.S. population. We were able to adjust for potential confounders and stratify by overweight status. To our knowledge, this is the first study investigating the interaction between leptin and CRP in relation to cancer in the population. A limitation of this study is that there was no information on cancer incidence, so that we were only able to assess these markers in relation to cancer mortality. In the NHANES, information on causes of death was collected by means of probabilistic matching [19]. Although we only selected those considered to have eligible mortality status, potential misclassification may have occurred. Low number of cases also hampered our stratification analyses, and therefore future studies with sufficient number of cases are necessary to further investigate this topic. Additionally, our analyses relied on a single measurement so that it may be prone to measurement error and within-person variation. The laboratory methods used for CRP measurement at the time the NHANES III was conducted were unable to perform a high sensitivity assay of this marker. Nevertheless, serum CRP in the NHANES III population was reported to be associated to CRP-related genetic variation [40], justifying the usefulness of this marker despite its limitation in quantitatively measuring low levels of CRP. Finally, abnormal levels of leptin and CRP may occur secondary to cancer which may result in reverse causation. We have excluded participants with cancer at baseline, however, residual confounding may have occurred.

Conclusion

Our study showed that leptin may be inversely associated with cancer mortality in women, and CRP corresponded with higher risk for cancer death in men. Interaction between CRP and leptin is likely to be minimal in the study on cancer mortality, unlike previous evidence suggested in cardiovascular disease. It is imperative for further studies to address the discrepancies in effects on cancer between adipokines and inflammatory markers in order to fully comprehend the mechanism linking obesity-related features and carcinogenesis. Furthermore, the differential associations with cancer death between men and women may point toward their potential use in future risk modification strategies targeting mortality from cancer.

Conflict of Interest

No conflict of interest declared.

References

1. Weisberg, S. P., D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Jr Ferrante. 2003. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796–1808.
2. Farooqi, I., and S. O’Rahilly. 2009. Leptin: a pivotal regulator of human energy homeostasis. Am. J. Clin. Nutr. 89:980–984.
3. Margetic, S., C. Gazzola, G. G. Pegg, and R. A. Hill. 2002. Leptin: a review of its peripheral actions and interactions. Int J Obes 26:1407–1433.
4. Liao, L. M., K. Schwartz, M. Pollak, B. I. Graubard, Z. Li, J. Ruterbusch, et al. 2013. Serum leptin and adiponectin levels and risk of renal cell carcinoma. Obesity (Silver Spring) 21:1478–1485.
5. Uddin, S., R. Bu, M. Ahmed, J. Abubaker, F. Al-Dayel, P. Bavi, et al. 2009. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol. Cancer. 8:74.
6. Ishikawa, M., J. Kitayama, and H. Nagawa. 2004. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin. Cancer Res. 10:4325–4331.
7. Niu, J., L. Jiang, W. Guo, L. Shao, Y. Liu, and L. Wang. 2013. The association between leptin level and breast cancer: a meta-analysis. PLoS ONE 8:e67349.
8. Ollberding, N. J. N., Y. Kim, Y. Y. B. Shvetsov, L. R. Wilkens, A. A. Franke, R. V. Cooney, et al. 2013. Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev. Res. (Phila.) 6:188–195.
9. Gross, A. L., C. J. Newschaffer, J. Hoffman-Bolton, N. Rifai, and K. Visvanathan. 2013. Adipocytokines,
inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol. Biomarkers Prev. 22:1319–1324.

10. Aleksandrova, K., H. Boeing, M. Jenab, H. B. Bueno-de-Mesquita, E. Jansen, F. J. B. van Duijn, et al. 2012. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res. 72:5328–5337.

11. Howe, L. R., K. Subbaramaiah, C. A. Hudis, and A. J. Dannenberg. 2013. Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin. Cancer Res. 19:6074–6083.

12. Khandekar, M. J., P. Cohen, and B. M. Spiegelman. 2011. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 11:886–895.

13. Fantuzzi, G., and R. Faggioni. 2000. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68:437–446.

14. Meyers, J. A., A. Y. Liu, A. McTiernan, M. H. Wener, B. Wood, D. S. Weigle, et al. 2008. Serum leptin concentrations and markers of immune function in overweight or obese postmenopausal women. J. Endocrinol. 199:51–60.

15. Johnson, A. R., J. J. Milner, and L. Makowski. 2012. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol. Rev. 249:218–238.

16. Visser, M., L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris. 1999. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131–2135.

17. Amrock, S. M., and M. Weitzman. 2014. Effect of increased leptin and C-reactive protein levels on mortality: results from the National Health and Nutrition Examination Survey. Atherosclerosis 236:1–6.

18. National, U. S. 1994. Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital. Health Stat. 1:1–407.

19. U.S. National Center for Health Statistics. 2015. NCHS Surveys. 2011 Linked Mortality Files. Public-Use Data Dictionary. Available from http://www.cdc.gov/nchs/data_access/data_linkage/mortality.htm.

20. Ruhl, C. E., and J. E. Everhart. 2001. Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am. J. Clin. Nutr. 74:295–301.

21. Romero-Corral, A., J. Sierra-Johnson, F. Lopez-Jimenez, R. J. Thomas, P. Singh, M. Hoffmann, et al. 2008. Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population. Nat. Clin. Pract. Cardiovasc. Med. 5:418–425.

22. Gunter, E. W., B. G. Lewis, and S. M. Koncikowski. 1996. Laboratory Procedures Used for the Third Health and Nutrition Examination Survey (NHANES III), 1988–1994.

23. Centers for Disease Control and Prevention. 2015. National health and nutrition examination survey. Available at http://www.cdc.gov/nchs/nhanes.htm

24. Jensen, M. D., D. H. Ryan, C. M. Apovian, J. D. Ard, A. G. Comuzzie, K. A. Donato, et al. 2013. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart association task force on practice guidelines and the obesity society. Circulation 129 (25 Suppl 2):S139–S140.

25. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497.

26. Chappell, R. 2012. Competing risk analyses: how are they different and why should you care? Clin. Cancer Res. 18:2127–2129.

27. Yu, H., D. Pardoll, and R. Jove. 2009. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9:798–809.

28. Vansaun, M. N. 2013. Molecular pathways: adiponectin and leptin signaling in cancer. Clin. Cancer Res. 19:1926–1932.

29. Matarese, G., S. Moschos, and C. S. Mantzoros. 2005. Leptin in immunology. J Immunol 174:3137–3142.

30. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140:883–899.

31. Ho, G. Y. F., T. Wang, M. J. Gunter, H. D. Strickler, M. Cushman, R. C. Kaplan, et al. 2012. Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res. 72:3029–3037.

32. Stattin, P., S. Söderberg, G. Hallmans, A. Bylund, R. Kaaks, U. H. Stenman, et al. 2001. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J. Clin. Endocrinol. Metab. 86:1341–1345.

33. Luhn, P., C. M. Dallal, J. M. Weiss, A. Black, W.-Y. Huang, J. V. Lacey, et al. 2013. Circulating adipokine levels and endometrial cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 22:1304–1312.

34. Liao, L. M., S. J. Weinstein, M. Pollak, Z. Li, J. Virtamo, D. Albanes, et al. 2013. Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis 34:109–112.

35. Baillargeon, J., E. A. Platz, D. P. Rose, B. H. Pollock, D. P. Ankerst, S. Haffner, et al. 2006. Obesity, adipokines, and prostate cancer in a prospective
population-based study. Cancer Epidemiol. Biomarkers Prev. 15:1331–1335.
36. Münzberg, H., M. Björnholm, S. H. Bates, and M. G. Myers. 2005. Leptin receptor action and mechanisms of leptin resistance. Cell. Mol. Life Sci. 62:642–652.
37. Chen, K., F. Li, J. Li, H. Cai, S. Strom, A. Bisello, et al. 2006. Induction of leptin resistance through direct interaction of C-reactive protein with leptin. Nat. Med. 12:425–432.
38. Shamsuzzaman, A. S. M., M. Winnicki, R. Wolk, A. Svatikova, B. G. Phillips, D. E. Davison, et al. 2004. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109:2181–2185.
39. Ble, A., B. G. Windham, S. Bandinelli, D. D. Taub, S. Volpato, B. Bartali, et al. 2005. Relation of plasma leptin to C-reactive protein in older adults (from the Invecchiare nel Chianti study). Am. J. Cardiol. 96:991–995.
40. Crawford, D. C., C. L. Sanders, X. Qin, J. D. Smith, C. Shephard, M. Wong, et al. 2006. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation 114:2458–2465.